CLAIMS

1. Use of semaglutide in the manufacture of a medicament for the treatment of mild cognitive impairment or Alzheimer’s disease.

2. The use according to claim 1 wherein said medicament is for the treatment of mild cognitive impairment.

3. The use according to claim 1 wherein said medicament is for the treatment of Alzheimer’s disease.

4. Use of semaglutide in the manufacture of a medicament for the treatment of preclinical Alzheimer’s disease, mild cognitive impairment of the Alzheimer’s type, early onset familial Alzheimer's disease, or prodromal Alzheimer's disease.

5. The use according to claim 4, wherein treatment is reducing the risk of developing preclinical Alzheimer’s disease, mild cognitive impairment of the Alzheimer’s type, early onset familial Alzheimer's disease, or prodromal Alzheimer's disease.

6. The use according to any one of claims 1-3, wherein treatment is reducing the risk of developing mild cognitive impairment or Alzheimer’s disease.

7. The use according to any one of the preceding claims, wherein said GLP-1 receptor agonist is the sole pharmaceutically active ingredient administered to said subject.

8. The use according to any one of the preceding claims, wherein said GLP-1 receptor agonist is administered subcutaneously, such as in the form of a solution or suspension, and optionally in the form of a solution comprising at least 90% water and with pH in the range of 7.0-9.0.

9. The use according to any one of the preceding claims, wherein said GLP-1 receptor agonist is administered orally, such as in the form of a tablet.

10. The use according to the preceding claim, wherein said GLP-1 receptor agonist is administered in the form of a tablet comprising at least 30% (w/w) salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, such as SNAC.

11. The use according to any one of the preceding claims, wherein said administration of a GLP-1 receptor agonist is a chronic treatment in which semaglutide is administered for at least 12 months, such as for at least 16 months or at least 18 months.

12. Use of semaglutide in the manufacture of a pharmaceutical composition for treating mild cognitive impairment or Alzheimer’s disease.

13. Use of semaglutide in the manufacture of a pharmaceutical composition for treating preclinical Alzheimer’s disease, mild cognitive impairment of the Alzheimer’s type, early onset familial Alzheimer's disease, or prodromal Alzheimer's disease

14. The use according to any one of claims 12-13, wherein said use is as defined in any one of claims 5-11.